Remote Deep Brain Stimulation Programming for Parkinson’s Disease: A Multicenter Randomized Non-Inferiority Trial
Objective: To evaluate the effectiveness and safety of remote vs. on-site DBS programming in Parkinson’s disease patients with STN-DBS. Background: Deep brain stimulation (DBS) is…Phase I randomized, double-blind study to evaluate feasibility, safety, and clinical responses of implanting autologous peripheral nerve tissue into the nucleus basalis of Meynert or substantia nigra for non-motor or motor symptoms in patients with Parkinson’s disease undergoing DBS surgery (STAR) Trial
Objective: To evaluate the feasibility, safety, and clinical responses of bilateral delivery, at the time of deep brain stimulation (DBS) surgery, of autologous peripheral nerve…LRRK2 Pathway Inhibition By NEU-411, a Potent, Selective, CNS-Penetrant LRRK2 Inhibitor In Healthy Participants
Objective: The aim of this work was to evaluate LRRK2 pathway modulation by the potent, selective, CNS-penetrant LRRK2 inhibitor NEU-411 in healthy adults and elderly…Results from the PRIME-UK Randomised Controlled Trial
Objective: To evaluate whether PRIME-Parkinson care increases the ability of people with parkinsonism (PwP) to achieve their personal goals, has a positive impact on health…Unilateral focused ultrasound subthalamotomy in early Parkinson’s disease: randomized-controlled trial protocol
Objective: To describe the protocol of a multicenter, prospective, randomized controlled trial (EarlyFocus II) which evaluates the efficacy and safety of unilateral magnetic resonance-guided focused…VGN-R09b, an Adeno-associated virus-based Combination Gene Replacement Therapy for Parkinson’s Disease
Objective: Develop a sustained disease modifying gene therapy for treating Parkinson’s disease Background: Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons…Tavapadon Is Not Associated With Increased Daytime Sleepiness in People With Parkinson’s Disease
Objective: To evaluate daytime sleepiness in people with Parkinson’s disease (PD) treated with tavapadon as monotherapy (TEMPO-1; NCT04201093) or adjunctive to levodopa (TEMPO-3; NCT04542499). Background:…The Benefits of Whole-Body Electro Muscle Stimulation (WB-EMS) in a patient with Parkinson’s Disease
Objective: To determine the motor and non-motor benefits of WB-EMS in a patient with Parkinson’s disease Background: Parkinson’s disease causes both motor and non-motor symptoms.…Functional and Neuroplastic Changes Following a 4-Week Non-Motorized Treadmill Training Program: A Pilot Study
Objective: The purpose of this study is to determine the neuroplastic effects on high-intensity gait training on gait parameters, motor disease severity, and quality of…Trends on recruitment and retention in Parkinson’s Disease modification trials
Objective: To identify the most common causes of participant’s screen failure (SF) and drop-out (DO) in Phase 2 and 3 Disease Modification Therapy (DMT) trials…
- « Previous Page
- 1
- …
- 295
- 296
- 297
- 298
- 299
- …
- 1942
- Next Page »